A Phase 1 interventional study of [Ac-225]-PSMA-62 (mCRPC) and [Ac-225]-PSMA-62 (OmHSPC) in Prostate Cancer, Metastatic Castration-resistant Prostate Cancer and Oligometastatic Prostate Carcinoma, sponsored by Eli Lilly and Company. Active, not recruiting at 7 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Prostatic Neoplasms by Eli Lilly and Company — 2 open to participants now, 8 under way, 3 of them phase 3. Prostatic Neoplasms · Eli Lilly and Company.
Among the 20 studies in Prostatic Neoplasms by Eli Lilly and Company, this one is the 10th largest by planned enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2024, is one of 7 in phase 1, and was the 17th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →2 of the 20 studies in Prostatic Neoplasms by Eli Lilly and Company are open now, in 10 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Canada, China and 4 more countries
Ages 18+
Eli Lilly and Company · Sites in United States, Australia, China and 5 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 3
First in 2007; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 142 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 142 across the 19 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
3 of the studies in Prostatic Neoplasms by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238479Eli Lilly and CompanyA Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | 2027-03 |
| NCT06465069Eli Lilly and CompanyA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | 2027-05 |
| NCT06229366Eli Lilly and Company[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer | 2027-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies in Prostatic Neoplasms by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
ACCEL is a multicenter, open label phase Ia/Ib/II study of [Ac-225]-PSMA-62 in participants with prostate-specific membrane antigen (PSMA)-positive prostate cancer.
The primary aim of the phase Ia study is to evaluate the safety and tolerability of [Ac-225]-PSMA-62 to determine the maximum tolerated dose (MTD). The primary aim of the randomized phase Ib dose optimization is to determine the recommended phase II doses (RP2D) for patients with mCRPC and OmHSPC. The aim of the phase II study for patients with mCRPC is to evaluate the efficacy of [Ac-225]-PSMA-62.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Criteria specific for patients with mCRPC:
Progressive mCRPC at the time of consent based on at least 1 of the following criteria being met in the context of castrate levels of testosterone:
Criteria specific for patients with OmHSPC:
PSA recurrence after radical prostatectomy (RP) or definitive radiation therapy (RT), with or without /salvage local therapy (radiation or surgery), with or without (neo)adjuvant ADT
Exclusion Criteria:
Criteria specific for patients with mCRPC:
Criteria specific for patients with OmHSPC:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with prostate cancer and biochemical recurrence after definitive surgery or radiation therapy, with 1-5 PSMA-positive lesions, who have not yet initiated lifelong hormone therapy.
Drug: [Ac-225]-PSMA-62 (OmHSPC)
Patients with PSMA-positive mCRPC who have prior treatment with at least one APRI and received taxane chemotherapy (or ineligible/refused); and received a maximum of 3 prior systemic therapy regimens in the mCRPC setting.
Drug: [Ac-225]-PSMA-62 (mCRPC)
Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week cycle for up to 4 cycles. Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 6-week or 4-week cycle, for a total of 4 cycles.
Phase Ia: Administered intravenously per dose escalation scheme. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle for up to 2 cycles. Phase Ib: Administered intravenously at MTD or one dose level below MTD. Patients will receive a single dose of \[Ac-225\]-PSMA-62 on Day 1 of each 8-week cycle, for a total of 2 cycles.
Maximum tolerated dose (MTD)
Phase Ia: Incidence of dose limiting toxicities (DLTs)
Time frame: From first dose of study drug through end of DLT period (4 weeks)
Safety, tolerability, and Recommended Phase II Dose (RP2D)
Phase 1b: Incidence and severity of treatment emergent adverse events (TEAEs)
Time frame: From first dose of study drug through end of treatment (~16 - 24 weeks)
Safety and tolerability
Phase Ia: Incidence and severity of treatment emergent adverse events (TEAEs)
Time frame: From first dose of study drug through end of treatment (~16 - 24 weeks)
The incidence of treatment emergent adverse events as assessed per CTCAE v5.0
To assess safety and tolerability of \[Ac-225\]-PSMA-62
Time frame: From first dose of study drug through end of study (~5 years)
Time to initiation of any life-long ADT, or other systemic hormonal therapies for prostate cancer
OmHSPC only: Preliminary efficacy assessment
Time frame: From first dose of study drug through end of study (~5 years)
Absorbed dose estimates (Gy) in normal organs
Evaluation of the biodistribution and radiation dosimetry of \[Ac-225\]-PSMA-62 to normal organs
Time frame: From first dose of study drug through end of treatment (~16 - 24 weeks)
The proportion of patients with a PSA change from baseline
To determine the effect of \[Ac-225\]-PSMA-62 on prostate-specific antigen (PSA) kinetics
Time frame: From first dose of study drug through efficacy follow-up period (up to approximately 3 years)
Objective Response Rate (ORR)
mCRPC only: Percentage of participants with a complete response (CR) or partial response (PR)
Time frame: From first dose of study drug until disease progression (up to approximately 3 years)
Radiographic progression free survival (rPFS)
Phase Ib mCRPC only: rPFS per investigator assessment
Time frame: From first dose of study drug until disease progression (up to approximately 3 years)
Patient Reported Outcome (PRO) - Pain
Phase Ib only: Measured by the change on the Brief Pain Inventory Short Form (BPI-SF) questionnaire, scored from 0 ('No pain', 'Does not interfere') to 10 ('Pain as bad as you can imagine', 'Completely interferes') on the severity and interference on daily functions of pain.
Time frame: From first dose of study drug until disease progression (up to approximately 3 years)
Patient Reported Outcome (PRO) - Impact of treatment toxicity
Phase Ib only: Measured by the change the Functional Assessment of Cancer Therapy (FACT-Item GP5) questionnaire, scored from 0 ('Not at all') to 4 ('Very much') on the interference of symptoms related to treatment emergent adverse events.
Time frame: From first dose of study drug until disease progression (up to approximately 3 years)
Started Apr 2024 (actual). Primary completion is estimated for Sep 2027, 41 months after the start.
Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 41 months is above that.
Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Actinium-225